Cargando…
Does Exist a Differential Impact of Degarelix Versus LHRH Agonists on Cardiovascular Safety? Evidences From Randomized and Real-World Studies
The main systemic therapy for the management of hormone-sensitive prostate cancer (PC) is androgen deprivation therapy (ADT), with the use of long-acting luteinizing hormone releasing-hormone (LHRH) agonists considered the main form of ADT used in clinical practice to obtain castration in PC. The co...
Autores principales: | Sciarra, Alessandro, Busetto, Gian Maria, Salciccia, Stefano, Del Giudice, Francesco, Maggi, Martina, Crocetto, Felice, Ferro, Matteo, De Berardinis, Ettore, Scarpa, Roberto Mario, Porpiglia, Francesco, Carmignani, Luca, Damiano, Rocco, Artibani, Walter, Carrieri, Giuseppe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237856/ https://www.ncbi.nlm.nih.gov/pubmed/34194398 http://dx.doi.org/10.3389/fendo.2021.695170 |
Ejemplares similares
-
A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer
por: Sciarra, Alessandro, et al.
Publicado: (2016) -
A Systematic Review and Meta-Analysis of Randomized Controlled Trials With Novel Hormonal Therapies for Non-Metastatic Castration-Resistant Prostate Cancer: An Update From Mature Overall Survival Data
por: Maggi, Martina, et al.
Publicado: (2021) -
Prospective assessment of two-gene urinary test with multiparametric magnetic resonance imaging of the prostate for men undergoing primary prostate biopsy
por: Busetto, Gian Maria, et al.
Publicado: (2020) -
Androgen-deprivation therapy and SARS-Cov-2 infection: the potential double-face role of testosterone
por: Salciccia, Stefano, et al.
Publicado: (2020) -
A systematic review and meta-analysis of clinical trials implementing aromatase inhibitors to treat male infertility
por: Del Giudice, Francesco, et al.
Publicado: (2019)